Difference between revisions of "Part:BBa K200013"
JamesField (Talk | contribs) (→Background) |
JamesField (Talk | contribs) (→EK Cleavage) |
||
Line 13: | Line 13: | ||
See 'Design Notes' for our rationale behind incorporating an EK cleavage sequence on the N terminus of the opiorphin pentapeptide. | See 'Design Notes' for our rationale behind incorporating an EK cleavage sequence on the N terminus of the opiorphin pentapeptide. | ||
+ | |||
+ | |||
+ | ==Side Effects== | ||
+ | |||
+ | A recent study involved genetically engineering retired breeder rats to constitutively express opiorphin. Interestingly, this resulted in the development of a priapic-like condition. It is thought that this condition resulted from the upregulation of the ornithine decarboxylase gene (ODC) by opiorphin. | ||
Revision as of 14:53, 18 October 2009
Opiorphin + EK cleavage site
Background
Opiorphin is a pentapeptide (five amino acids long) that was isolated from human saliva in 1996. Opiorphin acts as a pain killing agent. The amino acid sequence for opiorphin is Glutamine-Arginine-Phenylalanine-Serine-Arginine.
Mechanism of Action
Preliminary rat studies indicate that opiorphin has a pain killing effect six times stronger than that of morphine. With regards to its mechanism of action, opiorphin prevents the breakdown of enkephalins which are natural pain-killing opioids.
EK Cleavage
See 'Design Notes' for our rationale behind incorporating an EK cleavage sequence on the N terminus of the opiorphin pentapeptide.
Side Effects
A recent study involved genetically engineering retired breeder rats to constitutively express opiorphin. Interestingly, this resulted in the development of a priapic-like condition. It is thought that this condition resulted from the upregulation of the ornithine decarboxylase gene (ODC) by opiorphin.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]